What are the common adverse reactions after taking capmatinib?

Capmatinib is a targeted drug used to treat patients with non-small cell lung cancer carrying MET exon 14 skipping mutations. Although it shows good efficacy in controlling tumor progression, patients may experience some common adverse reactions while taking the drug. Understanding these side effects can help patients respond in a timely manner and ensure the safety of treatment.

First, the most common adverse reactions of capmatinib include edema and puffiness. Some patients may experience swelling of their limbs or face after taking the drug, which is usually caused by the drug affecting vascular permeability. Mild edema can be alleviated by adjusting living habits, such as raising limbs and reducing salt intake. However, if the edema is severe or affects daily activities, you should report it to your doctor in time and handle it accordingly.

Secondly, respiratory-related adverse reactions are also common, including cough, dyspnea and even the risk of interstitial lung disease. When patients experience persistent cough or difficulty breathing, they should seek medical treatment as soon as possible to rule out serious pulmonary complications. Doctors may adjust medication dosages or temporarily discontinue medication based on symptoms to ensure patient safety.

In addition, capmatinib may also cause gastrointestinal discomfort, such as nausea, diarrhea, loss of appetite, etc. To alleviate these symptoms, patients should maintain a balanced diet, avoid greasy and irritating foods, and use symptomatic drugs under the guidance of a doctor if necessary. Some patients may also experience fatigue, rash or abnormal liver function. Therefore, liver function and blood routine must be monitored regularly during treatment to detect and deal with abnormal reactions in a timely manner.

Generally speaking, most of the adverse reactions of capmatinib are controllable. Patients should maintain good communication and follow-up, and follow the doctor's instructions for rational medication use and life adjustments to maximize the treatment effect and quality of life.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib